137 related articles for article (PubMed ID: 7737904)
1. Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11.
Ogasawara H; Nishio K; Kanzawa F; Lee YS; Funayama Y; Ohira T; Kuraishi Y; Isogai Y; Saijo N
Jpn J Cancer Res; 1995 Jan; 86(1):124-9. PubMed ID: 7737904
[TBL] [Abstract][Full Text] [Related]
2. A novel antitumor antibiotic, KW-2189 is activated by carboxyl esterase and induces DNA strand breaks in human small cell lung cancer cells.
Ogasawara H; Nishio K; Takeda Y; Ohmori T; Kubota N; Funayama Y; Ohira T; Kuraishi Y; Isogai Y; Saijo N
Jpn J Cancer Res; 1994 Apr; 85(4):418-25. PubMed ID: 8200853
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin.
Niimi S; Nakagawa K; Sugimoto Y; Nishio K; Fujiwara Y; Yokoyama S; Terashima Y; Saijo N
Cancer Res; 1992 Jan; 52(2):328-33. PubMed ID: 1345810
[TBL] [Abstract][Full Text] [Related]
4. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a CPT-11-resistant human ovarian cancer cell line.
Kijima T; Kubota N; Nishio K
Anticancer Res; 1994; 14(3A):799-803. PubMed ID: 8074481
[TBL] [Abstract][Full Text] [Related]
6. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
Lee YS; Nishio K; Ogasawara H; Funayama Y; Ohira T; Saijo N
Cancer Res; 1995 Mar; 55(5):1075-9. PubMed ID: 7866991
[TBL] [Abstract][Full Text] [Related]
7. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Saijo N; Nishio K; Kubota N; Kanzawa F; Shinkai T; Karato A; Sasaki Y; Eguchi K; Tamura T; Ohe Y
Cancer Chemother Pharmacol; 1994; 34 Suppl():S112-7. PubMed ID: 8070019
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance.
Kanzawa F; Sugimoto Y; Minato K; Kasahara K; Bungo M; Nakagawa K; Fujiwara Y; Liu LF; Saijo N
Cancer Res; 1990 Sep; 50(18):5919-24. PubMed ID: 2168285
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
[TBL] [Abstract][Full Text] [Related]
10. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
[TBL] [Abstract][Full Text] [Related]
11. Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer.
Ohtsuka K; Inoue S; Kameyama M; Kanetoshi A; Fujimoto T; Takaoka K; Araya Y; Shida A
Lung Cancer; 2003 Aug; 41(2):187-98. PubMed ID: 12871782
[TBL] [Abstract][Full Text] [Related]
12. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Van Hattum AH; Pinedo HM; Schlüper HM; Hausheer FH; Boven E
Int J Cancer; 2000 Oct; 88(2):260-6. PubMed ID: 11004678
[TBL] [Abstract][Full Text] [Related]
13. Radiation sensitivities in various anticancer-drug-resistant human lung cancer cell lines and mechanism of radiation cross-resistance in a cisplatin-resistant cell line.
Oshita F; Fujiwara Y; Saijo N
J Cancer Res Clin Oncol; 1992; 119(1):28-34. PubMed ID: 1400562
[TBL] [Abstract][Full Text] [Related]
14. In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice.
Heike Y; Takahashi M; Ohira T; Arioka H; Funayama Y; Nishio K; Ogasawara H; Saijo N
Cancer Chemother Pharmacol; 1995; 35(3):200-4. PubMed ID: 7805177
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.
Kudoh S; Takada M; Masuda N; Nakagawa K; Itoh K; Kusunoki Y; Negoro S; Matsui K; Takifuji N; Morino H
Jpn J Cancer Res; 1993 Feb; 84(2):203-7. PubMed ID: 8385085
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.
Nomoto T; Nishio K; Ishida T; Mori M; Saijo N
Jpn J Cancer Res; 1998 Nov; 89(11):1179-86. PubMed ID: 9914787
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells.
Misawa T; Kikkawa F; Maeda O; Obata NH; Higashide K; Suganuma N; Tomoda Y
Jpn J Cancer Res; 1995 Jan; 86(1):88-94. PubMed ID: 7737915
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Mishra MN; Vangara KK; Palakurthi S
Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]